| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/06/2013 | US20130142769 Treatment of cognitive disorders |
| 06/06/2013 | US20130142768 Method for Improving Eye Health |
| 06/06/2013 | US20130142767 Composition containing reduced coenzyme q10, and manufacturing and stabilising methods therefor |
| 06/06/2013 | US20130142758 Novel hydroxamates as therapeutic agents |
| 06/06/2013 | US20130142757 Pyrazole derivatives |
| 06/06/2013 | US20130142730 Compounds and methods for the treatment of cancer |
| 06/06/2013 | US20130140210 Low-dosed solid oral dosage forms for hrt |
| 06/06/2013 | DE102012008730A1 Oral composition, useful e.g. as dietary supplement, comprises monounsaturated fatty acids comprising oleic acid e.g. oleic acid-((Z)-9-octadecenoic acid) in combination with peptides consisting of specific amino acids and/or antioxidant |
| 06/06/2013 | CA2857747A1 Treatment of b cell lymphomas |
| 06/06/2013 | CA2857712A1 Materials and methods related to nsaid chemoprevention in colorectal cancer |
| 06/06/2013 | CA2857694A1 Peptide deformylase inhibitors |
| 06/06/2013 | CA2857689A1 Aryl dihydropyridinones and piperidinones as mgat2 inhibitors |
| 06/06/2013 | CA2857664A1 Induced exon inclusion in spinal muscle atrophy |
| 06/06/2013 | CA2857592A1 Composition based on ubidecarenone |
| 06/06/2013 | CA2857546A1 Methods of treatment and prevention of eye diseases |
| 06/06/2013 | CA2857537A1 Thienyl[3,2-d]pyrimidin-4-one compounds, preparation method, pharmaceutical compositions and use thereof |
| 06/06/2013 | CA2857501A1 Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| 06/06/2013 | CA2857457A1 Dry coated tablet |
| 06/06/2013 | CA2857441A1 Carboxamide-substituted heteroaryl-pyrazoles and their use |
| 06/06/2013 | CA2857405A1 Poly (adp-ribose) polymerase inhibitor |
| 06/06/2013 | CA2857287A1 Peptide-mediated delivery of active agents across the blood-brain barrier |
| 06/06/2013 | CA2857226A1 Prophylactic compositions for management of microbial infections in patients with brain injury |
| 06/06/2013 | CA2857193A1 Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
| 06/06/2013 | CA2857164A1 Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases |
| 06/06/2013 | CA2857163A1 Pharmaceutical composition for preventing or treating hyperlipidemia |
| 06/06/2013 | CA2857156A1 Ropinirole-containing adhesive patch |
| 06/06/2013 | CA2857155A1 Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| 06/06/2013 | CA2857153A1 Methods for treating hyperbilirubinemia with stannsoporfin |
| 06/06/2013 | CA2857150A1 Purinone derivative hydrochloride |
| 06/06/2013 | CA2857008A1 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for retinal neuroprotection |
| 06/06/2013 | CA2856946A1 Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases |
| 06/06/2013 | CA2856839A1 Substituted anilines as ccr(4) antagonists |
| 06/06/2013 | CA2856831A1 Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists |
| 06/06/2013 | CA2856769A1 Novel 2h-indazoles as ep2 receptor antagonists |
| 06/06/2013 | CA2856722A1 Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
| 06/06/2013 | CA2856715A1 Compositions comprising 20-carbon fatty acids and methods of making and using same |
| 06/06/2013 | CA2856701A1 Phacetoperane for the treatment of attention-deficit hyperactivity disorder |
| 06/06/2013 | CA2856646A1 Combination treatment of cancer |
| 06/06/2013 | CA2856599A1 Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function |
| 06/06/2013 | CA2856592A1 Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent |
| 06/06/2013 | CA2856540A1 Anticoagulant reversal agents |
| 06/06/2013 | CA2856529A1 Compositions and methods for treating hepatitis c virus |
| 06/06/2013 | CA2856476A1 Use of aryl derivatives for controlling ectoparasites |
| 06/06/2013 | CA2856424A1 A method to enhance cognition |
| 06/06/2013 | CA2856334A1 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| 06/06/2013 | CA2855756A1 Non-hormonal steroid modulators of nf-kb for treatment of disease |
| 06/06/2013 | CA2855566A1 Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
| 06/06/2013 | CA2855242A1 Novel crystalline form of ticagrelor and process for the preparation thereof |
| 06/06/2013 | CA2855001A1 N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics |
| 06/06/2013 | CA2854266A1 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics |
| 06/06/2013 | CA2854208A1 Zero calorie polyphenol aqueous dispersions |
| 06/06/2013 | CA2852716A1 Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| 06/06/2013 | CA2850906A1 Transdermal therapeutic system for administering fentanyl or an analogue thereof |
| 06/06/2013 | CA2850705A1 2- (phenyl or pyrid - 3 - yl) aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
| 06/06/2013 | CA2850700A1 New bicyclic dihydroisoquinoline-1-one derivatives |
| 06/06/2013 | CA2850644A1 Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases |
| 06/06/2013 | CA2850594A1 Aminopyrimidine derivatives as lrrk2 modulators |
| 06/06/2013 | CA2850593A1 2-phenylaminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
| 06/06/2013 | CA2797350A1 Co-crystal intermediates of rosuvastatin and methods of using same |
| 06/05/2013 | EP2600147A2 Method for screening diabetes treating agent |
| 06/05/2013 | EP2599868A1 NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO c-Met AND USE THEREOF |
| 06/05/2013 | EP2599866A1 Novel nucleic acid having adjuvant activity and use thereof |
| 06/05/2013 | EP2599779A1 Dispiro 1,2,4-trioxolane antimalarials |
| 06/05/2013 | EP2599778A1 Diamide Compounds having Muscarinic Receptor Antagonist and Beta 2 Adrenergic Receptor Agonist Activity |
| 06/05/2013 | EP2599776A1 Therapeutic agent for neurological diseases |
| 06/05/2013 | EP2599775A1 Ethinyl-pyrazole derivative |
| 06/05/2013 | EP2599774A1 Condensed ring pyridine compound |
| 06/05/2013 | EP2599771A1 Naphthalene derivative |
| 06/05/2013 | EP2599767A1 Phenylbutyl-derivatives |
| 06/05/2013 | EP2599502A2 Method for preparation of site-specific protein conjugates |
| 06/05/2013 | EP2599499A1 Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| 06/05/2013 | EP2599498A1 Composition for ophthalmic disease associated with hypoxia or ischemia |
| 06/05/2013 | EP2599497A2 Porphyrazine-chemotherapeutic agents conjugates |
| 06/05/2013 | EP2599490A1 Anti-fatigue composition, formulation and use thereof |
| 06/05/2013 | EP2599489A1 AChE antisense deoxyoligonucleotide as an anti-inflammatory agent |
| 06/05/2013 | EP2599488A1 Vicenin 2 and derivatives thereof for use as an antispasmodic and/or prokinetic agent |
| 06/05/2013 | EP2599487A1 Therapeutic agent or prophylactic agent for neuropathic pain |
| 06/05/2013 | EP2599486A1 Dronedarone solid dispersion and preparation method thereof |
| 06/05/2013 | EP2599485A1 Fat-containing composition and oral formulation containing same |
| 06/05/2013 | EP2599484A1 Injectable pharmaceutical formulation of melphalan |
| 06/05/2013 | EP2599483A1 4-Phenylbutyric acid formulation |
| 06/05/2013 | EP2599482A1 Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate) |
| 06/05/2013 | EP2599481A1 4-phenylbutyric acid for the treatment or prevention of various diseases |
| 06/05/2013 | EP2599480A1 Compounds for the treatment of influenza |
| 06/05/2013 | EP2599479A1 4-phenylbutyric acid for the treatment of alzheimer's disease |
| 06/05/2013 | EP2599478A1 Transdermal therapeutic system for application of fentanyl or an analogue material thereof |
| 06/05/2013 | EP2599477A1 4-Phenylbutyric acid sustained release formulation |
| 06/05/2013 | EP2599475A2 Pharmaceutical composition having desirable bioavailability |
| 06/05/2013 | EP2599474A1 4-phenylbutyric acid for cosmetic use |
| 06/05/2013 | EP2599473A1 Astaxanthin-containing aqueous composition, cosmetic preparation, and method for suppressing degradation of astaxanthin |
| 06/05/2013 | EP2599386A1 2-aminopyrimidine modulators of the histamine h4 receptor |
| 06/05/2013 | EP2598873A2 Biomarkers for prostate cancer and methods using the same |
| 06/05/2013 | EP2598657A2 Microrna patterns for the diagnosis, prognosis and treatment of melanoma |
| 06/05/2013 | EP2598639A2 Sirna targeting vegfa and methods for treatment in vivo |
| 06/05/2013 | EP2598536A1 Process for the esterification of hyaluronic acid with hydrophobic organic compounds |
| 06/05/2013 | EP2598524A1 Regulation of glypican 4 activity to modulate the fate of stem cells and uses thereof |
| 06/05/2013 | EP2598513A1 Compounds and methods for treating neoplasia |
| 06/05/2013 | EP2598512A1 Vinylogous chalcone derivatives and their medical use |
| 06/05/2013 | EP2598508A1 Isoxazolo-quinazolines as modulators of protein kinase activity |
| 06/05/2013 | EP2598505A2 Substituted imidazo[1,2-b]pyridazines |